Latest Health News

PYC Therapeutics reported a 14.5% rise in income to AUD 26.17 million for FY2025 alongside a 33.3% increase in net loss, while increasing its stake in Vision Pharma to 97.1%. The auditor flagged material uncertainty over the company’s ability to continue as a going concern.

HPP has agreed to acquire Red Earth Energy Storage in a $40 million merger, aiming to relist on the ASX by early 2026 and capitalize on Australia’s growing battery storage market.

Bisalloy Steel Group reported steady revenue but strong profit growth and a significant dividend increase for FY25, while outlining ambitious expansion plans for FY26.

Icetana Limited posted a $2.9 million net loss for FY2025, with revenues down 49% due to lower non-recurring sales, while recurring SaaS income grew. The company secured a $3.6 million strategic partnership with SoftBank Robotics, strengthening its foothold in Japan.

Wiseway Group has delivered its strongest financial performance since listing, powered by a booming US division and a sharp focus on eCommerce imports across key markets.

Wiseway Group Limited has reported a remarkable 66% increase in revenue for FY2025, driven by strong operational performance and strategic expansion into the US market. The company also declared a final dividend, signalling confidence in its growth trajectory.

Pure Hydrogen Corporation has had its trading suspension lifted immediately following a capital raising announcement, signaling renewed market activity for the energy company.

humm Group Limited reported a remarkable 458% increase in net profit for FY25, driven by strong asset growth and effective cost management. The company also announced a final dividend and highlighted ongoing technology transformation and ESG commitments.

Aeris Resources has delivered a standout FY25 performance, posting a 78% rise in EBITDA and a 286% surge in net profit, driven by strong commodity prices and disciplined cost management.

Syntara Limited reported a significantly reduced loss for FY2025, driven by clinical progress and capital raises, while advancing its lead drug amsulostat with FDA Fast Track designation. The company also navigates ongoing payment disputes following the sale of its mannitol respiratory business.

The Agency Group has delivered a record financial performance in FY2025, with Gross Commission Income surpassing $125 million, driven by strong growth in residential sales and property management. The company’s unique national direct agency model and strategic expansion into emerging markets underpin its positive outlook.

Future Generation Global Limited reported a notable decline in half-year profits but raised its fully franked interim dividend, underscoring confidence in its investment strategy and ongoing commitment to youth mental health initiatives.